Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Prepaid Assets (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Prepaid Assets for 15 consecutive years, with $6.4 million as the latest value for Q1 2026.

  • For Q1 2026, Prepaid Assets fell 83.87% year-over-year to $6.4 million; the TTM value through Mar 2026 reached $6.4 million, down 83.87%, while the annual FY2025 figure was $40.7 million, 568.94% up from the prior year.
  • Prepaid Assets hit $6.4 million in Q1 2026 for Corcept Therapeutics, down from $40.7 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $40.7 million in Q4 2025 and bottomed at $4.6 million in Q3 2024.
  • Average Prepaid Assets over 5 years is $17.2 million, with a median of $15.9 million recorded in 2023.
  • Year-over-year, Prepaid Assets surged 568.94% in 2025 and then crashed 83.87% in 2026.
  • Corcept Therapeutics' Prepaid Assets stood at $16.4 million in 2022, then crashed by 64.19% to $5.9 million in 2023, then increased by 3.33% to $6.1 million in 2024, then soared by 568.94% to $40.7 million in 2025, then plummeted by 84.31% to $6.4 million in 2026.
  • According to Business Quant data, Prepaid Assets over the past three periods came in at $6.4 million, $40.7 million, and $6.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.